The What, Why, & How of Food Journaling for Diabetes
Food journaling can provide many benefits to patients with diabetes. Learn more about how this skill can help you gain more control over your…
This study is for patients with Type 2 Diabetes currently taking Ozempic, Trulicity, or Victoza. Instead of taking these meds, participants will switch to Tirzepatide (Mounjaro) for 3 months. Mounjaro is a once-weekly injection recently approved by the FDA for Type 2 Diabetes and has been shown to cause weight loss. The purpose of the study is to compare changes in A1C.
All participants enrolled in this study will receive Mounjaro at no charge and will be compensated for their time and travel.
To take part in the study, participants should be:
See if you qualify
CEO and Medical Director
Director of Clinical Services
Director of Clinical Research
Clinical Research Coordinator
Clinical Research Coordinator
Navigator/Study Start-up Manager
Clinical Research Coordinator
Clinical Research Coordinator